Everything below concerns regulatory status. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Derived from a fragment of human growth hormone |
| Sequence basis | hGH residues 176-191 | Commonly described as a 16-amino-acid fragment |
| Appearance | White to off-white powder | Typical for lyophilized research peptides |
| Solubility | Soluble in water or aqueous buffer | Exact solubility depends on pH and purity |
| Common synonyms | AOD9604; hGH 176-191 | Spelling and punctuation vary across sources |
== Production == In 2005, Canadian production was 10.5 million square metres (113 million square feet) (3⁄8 in or 9.5 mm basis) of which 8.78 million square metres (94.5 million square feet) were exported, almost entirely to the United States. In 2014, Romania became the largest OSB-exporting country in Europe, with 28% of the exports going to Russia and 16% to Ukraine.
== Hydrogen bonds between subunits == Hydrogen bonding networks between subunits has been shown to be important for the stability of the tetrameric quaternary protein structure. For example, a study of SDH which used diverse methods such as protein sequence alignments, structural comparisons, energy calculations, gel filtration experiments and enzyme kinetics experiments, could reveal an important hydrogen bonding network which stabilizes the tetrameric quaternary structure in mammalian SDH.
=== Translation termination === In 1973 Dalgarno and Shine proposed that in eukaryotes, the 3'-end of the small 18S rRNA may play a role in the termination of protein synthesis by complementary base pairing with termination codons. This came from their observation that the 3' terminal sequences of 18S rRNA from Drosophila melanogaster, Saccharomyces cerevisiae, and rabbit cells are identical: GAUCAUUA -3'OH. The conservation of this sequence between such distantly related eukaryotes implied that this nucleotide tract played an important role in the cell. Since this conserved sequence contained the complement of each of the three eukaryotic termination codons (UAA, UAG and UGA) it was proposed to have a role in the termination of protein synthesis in eukaryotes. A similar role for the 3' end of 16S rRNA in recognising termination triplets in E.coli was proposed in 1974 by Shine and Dalgarno on the basis of complementarity relationships between the 3'-terminal UUA-OH in 16S rRNA and E.coli termination codons. In F1 phage, a class of viruses that infect bacteria, the sequence coding for the first few amino acids often contains termination triplets in the two unused reading frames. In a commentary on this paper, it was noted that complementary base pairing with the 3'-terminus of 16S rRNA might serve to abort peptide bond formation after out-of-phase initiation.
The 'Dunkin' Donut' with a handle fashioned on it was discontinued in 2003 (except in Singapore) because it was hand-cut and uneconomical compared to machine-cut doughnuts. In 2004, the company's headquarters were relocated to Canton, Massachusetts. In December 2005, Dunkin' Donuts and Baskin-Robbins (by then, operating under the name Dunkin' Brands) were sold to a private equity consortium of Bain Capital, Carlyle Group, and Thomas H. Lee Partners for $2.4 billion. By 2010, Dunkin' Donuts' global sales were $6 billion. In June 2013, Dunkin' Donuts unveiled a new store design, the brand's first in almost seven years. The Dunkin' Donuts location in Natick, Massachusetts launched a program to test the concept of curbside pickup in December 2016. In January 2018, Dunkin' Donuts started opening new concept locations, beginning in Quincy, featuring modern decor, cold beverages on tap and a single-cup brewing machine, more packaged takeout options, and dedicated pick-up lines for mobile ordering inside and in the drive-thru. The concept was described as being part of a shift towards becoming an "on-the-go, beverage-led brand". In addition, the location, as well as others, began to trial signage referring to the chain as simply "Dunkin'"—removing "Donuts" from the name. In February 2018, Dunkin' announced plans to phase out polystyrene foam cups globally for environmental purposes by April 2020. In July 2018, Dave Hoffmann took over from Nigel Travis to become the CEO.
=== Brazil === Stroganoff is a popular dish in Brazil, where it is known as estrogonofe or strogonoff. Estrogonofe is generally prepared with tomato paste or ketchup and mushrooms. Chicken is sometimes used instead of beef. Estrogonofe is generally eaten with cooked white rice and shoestring fries (batata palha).
Sources: en.wikipedia.org
The company was founded by Colonel Eli Lilly, a pharmaceutical chemist and Union army veteran of the American Civil War. Lilly served as the company president until his death in 1898. In 1869, after working for drugstores in Indiana, Lilly became a partner in a Paris, Illinois-based drugstore with James W. Binford. Four years later, in 1873, Lilly left the partnership with Binford, and returned to Indianapolis. In 1874, Lilly partnered with John F. Johnston, and opened a drug manufacturing operation called Johnston and Lilly. In 1876, Lilly dissolved the partnership, and used his share of the assets to open his own pharmaceutical manufacturing business, Eli Lilly and Company, in Indianapolis. The sign outside, above the shop's door, read: "Eli Lilly, Chemist." The Indiana Historical Society recreated a replica of the first Lilly laboratory on Pearl Street for its exhibition, "You Are There: Eli Lilly at the Beginning," at the Eugene and Marilyn Glick Indiana History Center in Indianapolis. The temporary exhibition (1 October 2016, to 20 January 2018) also included costumed interpreters portraying Colonel Lilly and others. In 1886, Ernest G. Eberhardt, a chemist, joined the company as its first full-time research scientist. Lilly began his manufacturing venture with three employees, including his son, Josiah (J. K.). One of the first medicines that Lilly produced was quinine, a drug used to treat malaria, a mosquito-borne disease. By the end of 1876, sales reached $4,470. Around 1890, Col.
Iced tea can be purchased, like soda, in canned or bottled form at vending machines and convenience stores; usually, this pre-made tea is sweetened with corn syrup, and sometimes some other flavoring, such as lemon or raspberry, is added. Also, like other soft drinks, it can be purchased as a fountain drink, though in some establishments it is pumped from a bag-in-box, and in others, it is simply poured from a separate container that contains freshly brewed tea. In restaurants, iced tea is usually served unsweetened except in the Southeastern United States where iced tea is much more common and is available both sweet and unsweetened and "iced tea" is often considered to be "sweet tea" unless otherwise specified. The reason for the pre-sweetening is that it may be difficult to dissolve sugar in iced tea, even with constant stirring. The result can be insufficiently sweetened tea or gritty, undissolved sugar crystals in the tea. In the Northern United States and the Western United States, "tea" generally means the hot beverage and iced tea is referred to by name. Iced tea's popularity in the United States has led to an addition to standard cutlery sets; the iced tea spoon is a standard flatware teaspoon, but with a long handle, suitable for stirring sugar into the taller glasses commonly used for iced tea.
== Media == Cold Spring Record began publishing weekly in October 1899 and is still in publication. Tri-City Cable]: Channel 10 is the local public access television station for the communities of Richmond, Cold Spring and Rockville, broadcasting news on community events and coverage of local government meetings.
=== Economic situation === Because of their wide needs, the overall chelating agents growth was 4% annually during 2009–2014 and the trend is likely to increase. Aminopolycarboxylic acids chelators are the most widely consumed chelating agents; however, the percentage of the greener alternative chelators in this category continues to grow. The consumption of traditional aminopolycarboxylates chelators, in particular the EDTA (ethylenediaminetetraacetic acid) and NTA (nitrilotriacetic acid), is declining (−6% annually), because of the persisting concerns over their toxicity and negative environmental impact. In 2013, these greener alternative chelants represented approximately 15% of the total aminopolycarboxylic acids demand. This is expected to rise to around 21% by 2018, replacing and aminophosphonic acids used in cleaning applications. Examples of some Greener alternative chelating agents include ethylenediamine disuccinic acid (EDDS), polyaspartic acid (PASA), methylglycinediacetic acid (MGDA), glutamic diacetic acid (L-GLDA), citrate, gluconic acid, amino acids, plant extracts etc.
== Diagnosis == Detection of antibodies (cold or warm) and /or complement system on RBC from the patient is a direct Coombs antiglobulin test. Detection of antibodies in serum of the patient (still circulating in the blood, that have not yet formed any complexes with RBC) is an indirect Coombs antiglobulin test. A diagnosis of cold agglutinin disease may be made after several types of tests are performed by a health care provider. In some cases, the diagnosis is first suspected by chance if a routine complete blood count (CBC) detects abnormal clumping (agglutination) of the red blood cells. In most cases, the diagnosis is based on evidence of hemolytic anemia (from symptoms and/or blood tests). A person may also be physically examined for spleen or liver enlargement. An antiglobulin test (called the Coombs test) may be performed to determine the presence of a specific type of antibody. In people with cold agglutinin disease, the Coombs test is almost always positive for immunoglobulin M (IgM).
Sources: en.wikipedia.org
=== Neutering status in animals === In veterinary medicine, AMH measurements are used to determine neutering status in male and female dogs and cats. AMH levels can also be used to diagnose cases of ovarian remnant syndrome.
== History == Tacrolimus was discovered in 1987 by a Japanese team led by pharmacologist Tohru Kino; it was among the first macrolide immunosuppressants discovered, preceded by the discovery of rapamycin (sirolimus) on Rapa Nui (Easter Island) in 1975. It is produced by a soil bacterium, Streptomyces tsukubensis. The name tacrolimus is derived from "Tsukuba macrolide immunosuppressant". The early development (investigational new drug phase) of tacrolimus, called at the time by the development code FK-506, happened in the next several years. A firsthand account of that process is given in Thomas Starzl's 1992 memoir. Tacrolimus was first approved by the US Food and Drug Administration (FDA) in 1994, for use in liver transplantation; the indications were extended to include kidney transplants. The first generic version of tacrolimus (capsule for oral route) was approved in the US in 2009. A generic version of tacrolimus for injection was approved in the US in 2017. Tacrolimus was approved for medical use in the European Union in 2002, for the treatment of moderate to severe atopic dermatitis. In 2007, the indications were expanded to include the prophylaxis of transplant rejection in adult kidney or liver allograft recipients and the treatment of allograft rejection resistant to treatment with other immunosuppressive medicinal products in adults.
The three substrates of this enzyme are glycine betaine aldehyde, oxidised nicotinamide adenine dinucleotide (NAD+), and water. Its products are trimethylglycine, reduced NADH, and a proton. This enzyme belongs to the family of oxidoreductases, specifically those acting on the aldehyde or oxo group of donor with NAD+ or NADP+ as acceptor. The systematic name of this enzyme class is betaine-aldehyde:NAD+ oxidoreductase. Other names in common use include betaine aldehyde oxidase, BADH, betaine aldehyde dehydrogenase, and BetB. This enzyme participates in glycine, serine and threonine metabolism.
Diode-array spectrophotometers differed from the original spectrophotometer created by Beckman because it was the first single-beam microprocessor-controlled spectrophotometer that scanned multiple wavelengths at a time in seconds. It irradiates the sample with polychromatic light which the sample absorbs depending on its properties. Then it is transmitted back by grating the photodiode array which detects the wavelength region of the spectrum. Since then, the creation and implementation of spectrophotometry devices has increased immensely.
== Licensing and regulation == In the European Union, in the scope of medical devices, the European Court places them in some relation to a specific medical purpose: treating a disease or illness. The Court held that regulating devices that do not explicitly manifest medical benefits as medical devices would run counter to the rationale and lead to overregulation. "The legal foundation for regulating medical devices in the EU is the MDR (Regulation (EU) 2017/745), which was adopted in 2016 and came into effect in 2021. The MDR stipulates that for non-medical devices, the 'requirement to demonstrate a clinical benefit (…) shall be understood as a requirement to demonstrate the performance of the device' (Article 61 para 9 MDR). In other words, devices must demonstrate that they function in the way claimed by manufacturers, instead of showing a therapeutic benefit. Moreover, with respect to the safety of non-medical Annex XVI devices, the MDR lays down the following: For the devices referred to in Annex XVI, the general safety requirements (…) shall be understood to mean that the device, when used under the conditions and for the purposes intended, does not present a risk at all or presents a risk that is no more than the maximum acceptable risk related to the product's use which is consistent with a high level of protection for the safety and health of persons(MDR, Annex I, Article 9). The MDR sets an absolute risk threshold for the non-medical devices listed in Annex XVI, including non-invasive brain stimulation.
Sources: en.wikipedia.org
No, it is a synthetic peptide fragment corresponding to a small portion of hGH. It is not the full 191-amino-acid hormone and does not reproduce all of hGH's effects.
It is commonly described as a 16-amino-acid peptide based on residues 176-191 of human growth hormone. Some sources vary in notation, so checking the stated sequence is useful.
It is not typically described as a standalone natural hormone. The sequence is derived from the C-terminal region of human growth hormone, but the synthetic peptide is a laboratory-made construct.
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.